Trevena, Inc. (TRVN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Trevena, Inc. (TRVN) trades at $0.001 with AI Score 49/100 (Grade C). Trevena, Inc. is a biopharmaceutical company focused on developing novel medicines for central nervous system disorders, including pain and migraine. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for TRVN: TRVN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRVN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TRVN: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Trevena, Inc. (TRVN) Healthcare & Pipeline Overview
Trevena, Inc. is a biopharmaceutical firm developing novel G protein biased ligand medicines for central nervous system disorders, including moderate-to-severe acute pain with its commercialized product OLINVYK, and other candidates targeting migraine and chronic pain, positioning it within the specialized pain management and neurological therapeutics market.
What Is the Investment Thesis for TRVN?
Trevena, Inc.'s investment thesis centers on its specialized drug development platform, focusing on G protein biased ligands for central nervous system disorders, particularly pain management. The company's lead product, OLINVYK (Oliceridine) injection, represents a commercialized asset for moderate-to-severe acute pain, providing a foundation for potential revenue generation. The broader pipeline, including TRV027 for COVID-19 related acute lung injury (in collaboration with Imperial College London), TRV250 for acute migraine, and TRV734 and TRV045 for various forms of pain, offers multiple potential growth catalysts. The company's strategy to address large therapeutic markets with novel mechanisms of action could drive future value. However, the company currently operates with a significant negative profit margin of -1289.2% and a market capitalization of $0.00B, indicating a pre-profitability or early-stage commercialization profile typical of biotechnology firms. The success of pipeline candidates through clinical trials and subsequent commercialization will be critical value drivers, alongside managing its financial burn rate.
Based on FMP financials and quantitative analysis
TRVN Key Highlights
Market Capitalization of $0.00B, reflecting its current valuation within the biotechnology sector.
- Profit Margin of -1289.2%, indicating significant investment in research and development and early commercialization phases.
- Gross Margin of 46.6%, suggesting a notable margin on its commercialized product, OLINVYK, before operating expenses.
- Beta of 0.56, indicating lower volatility relative to the broader market, which can be atypical for a biotechnology company.
- Employee count of 23, highlighting a lean operational structure for a biopharmaceutical company with multiple pipeline assets.
Who Are TRVN's Competitors?
TRVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRVN's Key Strengths?
Commercialized product OLINVYK for moderate-to-severe acute pain.
- Diverse pipeline of G protein biased ligand candidates targeting significant CNS markets.
- Strategic collaboration with Imperial College London for TRV027.
- Proprietary drug discovery platform focused on novel mechanisms of action.
What Are TRVN's Weaknesses?
Significant negative profit margin of -1289.2% indicating unprofitability.
- Small market capitalization of $0.00B, suggesting limited financial scale.
- Reliance on successful clinical development and commercialization of pipeline assets.
- Limited employee base of 23, potentially constraining R&D and commercialization efforts.
What Could Drive TRVN Stock Higher?
TRVN catalyst: Further commercialization efforts and market penetration for OLINVYK (Oliceridine) injection in the acute pain market.
- Advancement of TRV027 through clinical development for acute lung injury and blood clotting in COVID-19 patients, potentially reaching key milestones in its collaboration with Imperial College London.
- Progress in the clinical trials and regulatory pathway for TRV250, targeting acute migraine, moving closer to potential market entry.
- Development milestones for TRV734 and TRV045, as they advance through preclinical or clinical stages for various chronic and acute pain indications.
What Are the Key Risks for TRVN?
Financial-distress signal — its Altman Z-Score of -48.18 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -1289.2% poses a risk to long-term financial sustainability and requires ongoing capital investment.
- Clinical trial failures or delays for pipeline candidates (TRV027, TRV250, TRV734, TRV045) could significantly impact future revenue potential and company valuation.
- Regulatory hurdles and the inability to secure necessary approvals for new drug candidates could prevent market entry and commercialization.
- Intense competition within the biotechnology and pharmaceutical sectors, particularly in the pain management and CNS disorder markets, could limit market share for Trevena's products.
- Challenges in achieving widespread market adoption and favorable reimbursement for OLINVYK and future approved products.
What Are the Growth Opportunities for TRVN?
- **OLINVYK Commercialization Expansion:** The ongoing commercialization of OLINVYK (Oliceridine) injection for moderate-to-severe acute pain represents a primary growth driver. The acute pain market is a significant segment within healthcare, with a continuous need for effective and differentiated pain management options. Trevena's focus on a G protein biased mu-opioid receptor ligand aims to offer a new therapeutic choice. Expanding market penetration, securing broader formulary access, and increasing prescriber adoption for OLINVYK could substantially grow revenue. The success in this area is critical for establishing a commercial footprint and generating sustainable income to support further pipeline development.
- **TRV027 Development for COVID-19 Complications:** The development of TRV027 for acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients presents a unique growth opportunity. While the immediate pandemic phase may have evolved, the need for treatments addressing severe respiratory complications and coagulopathies remains relevant for future viral outbreaks or severe respiratory illnesses. The collaboration with Imperial College London provides external validation and expertise, potentially accelerating development and positioning Trevena to address critical unmet needs in respiratory medicine.
- **TRV250 for Acute Migraine Treatment:** TRV250, a G protein biased delta-opioid receptor agonist, targets the substantial acute migraine market. Migraine affects millions globally, and while several treatments exist, there is still a demand for novel mechanisms of action that offer improved efficacy, tolerability, or fewer side effects. Successful clinical development and eventual commercialization of TRV250 could tap into a large patient population seeking rapid and effective relief from acute migraine attacks, potentially establishing Trevena in the neurology therapeutic area beyond pain.
- **TRV734 for Moderate-to-Severe Acute and Chronic Pain:** The development of TRV734, another G protein biased ligand of the MOR, for both moderate-to-severe acute and chronic pain, expands Trevena's reach within the vast pain management market. Chronic pain, in particular, represents a massive and often underserved patient population with significant unmet needs for long-term, non-addictive, and effective treatments. Advancing TRV734 through clinical trials and demonstrating a compelling profile could position Trevena to capture a share of this market, offering a potential successor or complementary therapy to OLINVYK.
- **TRV045 for Chronic Pain Management:** TRV045, a novel S1P modulator, represents a distinct mechanistic approach for managing chronic pain. This diversification in mechanism of action could open new therapeutic avenues for Trevena. Chronic pain is a complex condition, and therapies with different targets may offer benefits to patient populations unresponsive to traditional treatments. Successful development of TRV045 could provide Trevena with a differentiated product in the highly competitive chronic pain landscape, potentially addressing specific neuropathic or inflammatory pain conditions.
What Are TRVN's Competitive Advantages?
- Proprietary G protein biased ligand platform, offering a differentiated approach to drug discovery.
- Approved product OLINVYK (Oliceridine) injection, providing a commercialized asset in the acute pain market.
- Diverse pipeline of drug candidates targeting various CNS disorders, reducing reliance on a single asset.
- Strategic collaboration with Imperial College London for TRV027, leveraging external expertise and resources.
What Does TRVN Do?
Trevena, Inc., incorporated in 2007 and headquartered in Chesterbrook, Pennsylvania, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for patients affected by central nervous system (CNS) disorders. The company's strategic focus leverages its expertise in G protein biased mu-opioid receptor (MOR) ligands to create differentiated therapeutic options. Its lead product, OLINVYK (Oliceridine) injection, has been developed for the management of moderate-to-severe acute pain, representing a key commercial asset for the company. Beyond OLINVYK, Trevena maintains a pipeline of product candidates addressing significant unmet medical needs. This includes TRV027, which is being evaluated for its potential in treating acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19, a program supported by a collaboration with Imperial College London. The pipeline further extends to TRV250, a G protein biased delta-opioid receptor agonist designed for the treatment of acute migraine, and TRV734, a small molecule G protein biased ligand of the MOR intended for both moderate-to-severe acute and chronic pain. Additionally, TRV045, a novel S1P modulator, is under development for managing chronic pain. With a team of 23 employees, Trevena operates within the highly specialized and competitive biotechnology industry, aiming to bring forward new therapeutic paradigms for complex CNS conditions.
What Products and Services Does TRVN Offer?
- Develops novel medicines for central nervous system (CNS) disorders.
- Focuses on G protein biased ligands, a specific drug development approach.
- Commercializes OLINVYK (Oliceridine) injection for moderate-to-severe acute pain.
- Is developing TRV027 for acute lung injury and blood clotting in COVID-19 patients.
- Has TRV250 in its pipeline for the treatment of acute migraine.
- Is advancing TRV734 for moderate-to-severe acute and chronic pain.
- Is developing TRV045, a novel S1P modulator, for chronic pain management.
- Collaborates with Imperial College London on the TRV027 program.
How Does TRVN Make Money?
- Research and development of proprietary drug candidates for CNS disorders.
- Commercialization and sales of approved pharmaceutical products, such as OLINVYK.
- Seeking regulatory approvals for pipeline assets through clinical trials.
- Potentially engaging in strategic collaborations or licensing agreements for drug development and commercialization.
What Industry Does TRVN Operate In?
Trevena, Inc. operates within the highly dynamic and research-intensive biotechnology industry, specifically focusing on central nervous system (CNS) disorders, including pain and migraine. This sector is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. The global pain management market alone is substantial, driven by an aging population and increasing prevalence of chronic conditions. Trevena's approach, utilizing G protein biased ligands, positions it in a niche within the broader pharmaceutical landscape, aiming to develop drugs with potentially improved efficacy or safety profiles compared to existing treatments. Competition is intense, with numerous pharmaceutical giants and smaller biotech firms vying for market share in pain, migraine, and other CNS indications. Trevena's ability to differentiate its pipeline candidates and secure market adoption for OLINVYK will be crucial for its competitive standing in this evolving industry.
Who Are TRVN's Key Customers?
- Patients suffering from moderate-to-severe acute pain.
- Patients with acute lung injury and abnormal blood clotting due to COVID-19.
- Individuals experiencing acute migraine.
- Patients with moderate-to-severe acute and chronic pain.
- Healthcare providers, hospitals, and clinics that prescribe and administer pain and neurological treatments.
Company Profile
Trevena, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chesterbrook, US. The company is led by CEO Carrie L. Bourdow. TRVN has traded publicly since 2014.
Trevena, Inc. Financial Trajectory
Trevena, Inc. (TRVN) reported $283K in revenue for Q3 2024, a decline of 12.9% compared to the prior quarter. The company recorded a net loss of $4.9M, with diluted EPS of $-5.79. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare.
How Trevena, Inc. Is Valued
Relative to its peer group, TRVN's quantitative score of 49/100 is below the peer average of 76/100.
Key Financial Metrics
Return on assets is -99.2%, showing how much profit it generates from its asset base. A current ratio of 4.66 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Trevena, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.18 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Trevena, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1565.8% below estimates on average.
Forward Outlook
Wall Street analysts project Trevena, Inc. revenue of about $3.0M for fiscal 2026, with EPS near $-0.42.
TRVN Financials
Bull Case vs Bear Case
Bull Case
- Trevena's recent insider buying suggests that those with the deepest knowledge of the company believe it's undervalued. It's like Musk buying more Tesla shares – a strong signal.
- The community chatter seems to be leaning towards optimism about Trevena's pipeline potential. Positive sentiment can drive momentum, similar to what we saw with meme stocks, but based on potential.
- There's a growing perception that Trevena's addressing a real need in post-operative pain management, which could lead to increased market adoption. Think of it as finding a niche like Beyond Meat did with plant-based alternatives.
- Recent market developments suggest a renewed interest in smaller biotech firms with promising late-stage drugs. It's a 'rising tide lifts all boats' scenario, reminiscent of the dot-com boom's early days.
Bear Case
- Despite insider buying, the overall market sentiment towards small-cap biotechs remains cautious. Investors are still wary after many disappointments in the sector.
- Community sentiment can be fickle; today's darling can be tomorrow's disappointment. Remember the initial hype around Theranos?
- The market perception is that Trevena faces stiff competition from established players in the pain management space. Breaking through that barrier is a huge challenge, like Blockbuster trying to compete with Netflix.
- Recent market developments indicate increased regulatory scrutiny on new pain medications, which could delay or hinder Trevena's drug approvals. The FDA can be unpredictable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $283,000 | -$5M | -$5.79 |
| Q2 2024 | $325,000 | -$5M | -$5.74 |
| Q1 2024 | $20,000 | -$8M | -$9.01 |
Based on FMP financials and quantitative analysis
TRVN Latest News
No recent news available for TRVN.
TRVN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRVN.
Price Targets
Wall Street price target analysis for TRVN.
TRVN MoonshotScore
What does this score mean?
The MoonshotScore rates TRVN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Carrie L. Bourdow
CEO
Unknown. No specific background details, education, or previous roles were provided in the source data beyond her name and title.
Track Record: Unknown. No specific achievements, strategic decisions, or company milestones under her leadership were provided in the source data.
TRVN OTC Market Information
Trevena, Inc. trades on the OTC Other tier, which is the lowest of the three primary OTC Markets tiers (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are typically those that do not meet the financial or disclosure requirements for OTCQX or OTCQB, or that have not provided current information to OTC Markets. This tier is often associated with companies that have limited public disclosure, making it challenging for investors to access comprehensive financial and operational data. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements and regulatory oversight, OTC Other companies face fewer disclosure obligations.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors may lack critical financial and operational data to make informed decisions.
- Low Liquidity: Trading on OTC Other often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares.
- Price Volatility: Shares can experience significant price fluctuations due to limited trading activity and lack of market depth.
- Fraud Risk: The less stringent regulatory environment on OTC markets, particularly lower tiers, can expose investors to a higher risk of fraud or manipulation.
- Difficulty in Valuation: Lack of comprehensive and timely financial disclosures makes fundamental valuation challenging for investors.
- Verify any available financial statements directly from the company or regulatory filings, if accessible.
- Research the company's management team and their professional history.
- Scrutinize all available news releases and company announcements for operational updates.
- Understand the market depth and typical trading volumes for the stock before considering investment.
- Assess the company's business model and product pipeline for commercial viability and regulatory progress.
- Investigate any legal or regulatory actions against the company or its management.
- Confirm the company's headquarters and operational presence.
- Established incorporation date in 2007, indicating a history of operation.
- Commercialized product, OLINVYK (Oliceridine) injection, suggesting a tangible asset and revenue potential.
- Named CEO, Carrie L. Bourdow, providing clear leadership identification.
- Collaboration with a reputable institution, Imperial College London, for TRV027 development.
TRVN Healthcare Stock FAQ
What does the AI Score mean for TRVN?
TRVN holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Trevena, Inc. is a biopharmaceutical company focused on developing novel medicines for central nervous system disorders, including pain and migraine. Its pipeline features OLINVYK for acute pain …
What is Trevena, Inc.'s drug pipeline status?
Trevena, Inc. has a pipeline focused on central nervous system disorders, utilizing a G protein biased ligand approach. Its lead product, OLINVYK (Oliceridine) injection, is approved and commercialized for moderate-to-severe acute pain.
What revenue streams does Trevena, Inc. have in healthcare?
Trevena, Inc.'s primary current revenue stream in healthcare is derived from the commercialization and sales of its approved product, OLINVYK (Oliceridine) injection, which is indicated for the management of moderate-to-severe acute pain.
What are the main risks for TRVN?
Investing in Trevena, Inc. carries several notable risks, typical of a biotechnology company. A primary concern is the company's significant negative profit margin of -1289.2%, indicating ongoing unprofitability and a reliance on external funding for operations and pipeline advancement.
What are the key factors to evaluate for TRVN?
Trevena, Inc. (TRVN) holds an AI score of 49/100 (low). Trevena, Inc.'s investment thesis centers on its specialized drug development platform, focusing on G protein biased ligands for central nervous system disorders, particularly pain management. Not financial advice.
How frequently does TRVN data refresh on this page?
TRVN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TRVN's recent stock price performance?
Trevena, Inc. (TRVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercialized product OLINVYK for moderate-to-severe acute pain. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRVN overvalued or undervalued right now?
Trevena, Inc. (TRVN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRVN before investing?
Before investing in Trevena, Inc. (TRVN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived solely from the provided source data.
- No external information or speculative content has been used.